Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 34Leukemia 15Gastrointestinal Stromal Tumors 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Leukemia, Myeloid, Chronic-Phase 7Philadelphia Chromosome 4Leukemia, Myeloid 4Bone Marrow Diseases 4Neoplasms 3Myeloproliferative Disorders 3Hematologic Diseases 3Melanoma 2Hematologic Neoplasms 2Bronchiolitis Obliterans Syndrome 2Blast Crisis 2Synovitis, Pigmented Villonodular 1Recurrence 1Piebaldism 1Peritoneal Neoplasms 1Ovarian Neoplasms 1Neurofibromatoses 1Neurofibroma, Plexiform 1Neurofibroma 1Neoplastic Processes 1Neoplasms by Histologic Type 1Neoplasm Metastasis 1Mastocytosis, Systemic 1Leukemia, Myeloid, Accelerated Phase 1Hypereosinophilic Syndrome 1Glioma 1

Interventions

Trastuzumab 243Paclitaxel 193Cyclophosphamide 158Docetaxel 134Letrozole 113Capecitabine 113Fulvestrant 106Doxorubicin 103Bevacizumab 87Carboplatin 81exemestane 80Anastrozole 79Lapatinib 70Tamoxifen 69Albumin-Bound Paclitaxel 57palbociclib 54pertuzumab 53Taxes 51Gemcitabine 50Radiotherapy 46eribulin 43pembrolizumab 41Everolimus 41Ado-Trastuzumab Emtansine 41Vinorelbine 38130-nm albumin-bound paclitaxel 35ixabepilone 32Epirubicin 28pegfilgrastim 25liposomal doxorubicin 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Breast Neoplasms × nilotinib × Clear all
NCT05185947 2026-05-29

Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
21 enrolled 21 charts
BreastGastrointestinalGynecologic

Appendiceal Neoplasms, Breast Neoplasms, Genital Neoplasms, Female, Ovarian Neoplasms, Peritoneal Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡